Epstein-Barr virus expression in Hodgkin's disease in relation to patient characteristics, serum factors and blood lymphocyte function

British Journal of Cancer

Volumn 81, Issue 7, 1999, Pages 1182-1187

  Axdorph, U ^a   Porwit MacDonald, A ^b   Sjoberg J ^a   Grimfors, G ^a   Ekman, M ^b   Wang, W ^b   Biberfeld, P ^b   Bjorkholm M ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Epstein Barr virus; Hodgkin's disease; Lymphocyte function; Prognosis; s ICAM 1; sCD30

Indexed keywords

BETA 2 MICROGLOBULIN; BLEOMYCIN; CD30 ANTIGEN; CD4 ANTIGEN; CD5 ANTIGEN; CHLORMETHINE; CONCANAVALIN A; DACARBAZINE; DNA; DOXORUBICIN; IMMUNOGLOBULIN G ANTIBODY; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 2 RECEPTOR; LATENT MEMBRANE PROTEIN 1; PROCARBAZINE; THYMIDINE KINASE; VINBLASTINE; VINCRISTINE; VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; CANCER REGRESSION; CANCER SURVIVAL; CLINICAL FEATURE; CONTROLLED STUDY; DNA SYNTHESIS; EPSTEIN BARR VIRUS; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LEUKOCYTE COUNT; LYMPHOCYTE FUNCTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TUMOR BIOPSY; VIRUS INFECTION;

EID: 0032712989     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6690827     Document Type: Article

References (49)

1. Armitage P and Berry G (1987) Statistical Methods in Medical Research, 2nd edn, pp. 125-132. Blackwell, Cambridge
2. Axdorph U, Grimfors G, Landgren O, Giscombe R, Johansson B and Björkholm M (1995) Serum levels of sICAM-1 are correlated to tumour burden and blood lymphocyte functions in untreated Hodgkin's disease. Third International Symposium on Hodgkin's Lymphoma, Köln (abstract)
3. Bibeau F, Brousset P, Knecht H, Meggetto F, Drouet E, Rubin B and Delsol G (1994) Epstein Barr virus replication in Hodgkin's disease. Bull Cancer 81: 114-118
4. Björkholm M, Holm G, Mellstedt H, Johansson B and Askergren J (1977) Prognostic factors in Hodgkin's disease. I. Analysis of histopathology, stage distribution and results of therapy. Scand J Haematol 19: 487-495
5. Björkholm M, Holm G, Mellstedt H, Johansson B, Killander D, Sundblad R and Söderberg G (1978) Prognostic factors in Hodgkin's disease. II. The role of lymphocyte defect. Scand J Haematol 20: 306-308
6. Björkholm M, Axdorph U, Grimfors G, Merk K, Johansson B, Svedmyr E, Mellstedt H and Holm G (1995) Fixed versus response adapted MOPP/ABVD chemotherapy in Hodgkin's disease. Ann Oncol 6: 895-899
7. Brousset P, Knecht H, Rubin B, Drouet E, Chittal S, Meggetto F, Saati TA, Bachmann E, Denoyel G, Sergeant A and Delsol G (1993) Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. Blood 82: 872-876
8. Carbone PP, Kaplan HS, Musshoff K, Smithers DW and Tubiana M (1971) Report of the Committee on Hodgkin's disease staging classification. Cancer Res 31: 1860-1861
9. Cordell JL, Falini B, Erber WN, Ghosh AK, Abdulaziz Z, MacDonald S, Pulford KA, Stein H and Mason DY (1984) Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP complexes). J Histochem Cytochem 32: 219
10. Dougherty G, Murdoch S and Hogg N (1988) The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 18: 35-39
11. Enblad G, Sandvej K, Lennette E, Sundström C, Klein G, Glimelius B and Pallesen G (1997) Lack of correlation between EBV serology and presence of EBV in the Hodgkin and Reed-Sternberg cells of patients with Hodgkin's disease. Int J Cancer 72: 394-397
12. Frisan T, Sjöberg J, Dolcetti R, Boiocchi M, de Re V, Carbone A, Brautbar C, Battat S, Biberfeld P, Ekman M, Christensson B, Sundström C, Björkholm M, Pisa P and Masucci MG (1995) Local suppression of Epstein-Barr virus (EBV) specific cytotoxicity in biopsies of EBV-positive Hodgkin's disease. Blood 86: 1493-1501
13. Grimfors G, Andersson B, Tullgren O, Giscombe R, Holm G, Johansson B and Björkholm M (1992) Increased serum CD 8 soluble antigen level is associated with blood lymphocyte abnormalities and other established indicators of poor prognosis in adult Hodgkin's disease. Br J Haematol 80: 166-171
14. Groux H, Bigler M, de Vries JE and Roncarolo MG (1996) Interleukin-10 induces a long term antigen-specific anergic state in human CD4+ T cells. J Exp Med 184: 19-29
15. Gruss HJ and Hermann F (1996) CD30 ligand, a member of the TNF ligand superfamily, with growth and activation control for CD30+ lymphoid and lymphoma cells. Leukemia and Lymphoma 20: 397-409
16. Gruss HJ, Scheffran I, Hubinger G, Duyster J and Herrman F (1996) The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia 10: 829-835
17. Harris LN (1995) A practical approach to the pathology of lymphoid neoplasms: a revised European-American classification from the international lymphoma study group. In: Important Advances in Oncology, De Vita, Hellman and Rosenberg (eds), pp. 111-140. JB Lippincott: Philadelphia
18. Henle W, Henle GE and Horwitz CA (1974) Epstein Barr virus specific diagnostic tests in infectious mononucleosis. Hum Pathol 5: 551-565
19. Herbst H, Dallenbach F, Hummel M, Niedobitek G, Pileri S, Muller Lantsch N and Stein H (1991) Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci USA 88: 4766-4770
20. Herbst H, Foss HD, Samol J, Araujo I, Klotzbach H, Krause H, Agathanggelou A, Niedobitek G and Stein H (1996) Frequent expression of interleukin-10 in Epstein-Barr virus-harboring tumour cells of Hodgkin's disease. Blood 87: 2918-2929
21. Kaczorowski S, Kaczorowska M and Christensson B (1994) Expression of EBV encoded latent membrane protein 1 (LMP-1) and bcl-2 protein in childhood and adult Hodgkin's disease: application of microwave irradiation for antigen retrival. Leukemia Lymphoma 13: 273-283
22. Kanavaros P, Jiwa M, van der Valk P, Walboomers J, Horstman A and Meijer C (1993) Expression of Epstein-Barr virus latent gene products and related cellular activation and adhesion molecules in Hodgkin's disease and non-Hodgkin's lymphomas arising in patients without overt pre-existing immunodeficiency. Hum Pathol 24: 725-729
23. Khanna R, Burrows SR, Nicholls J and Poulsen LM (1998) Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP 1): evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP 1-specific cytotoxic T lymphocytes. Eur J Immunol 28: 451-458
24. Knecht H, McQuain C, Martin J, Rothenberger S, Drexler HG, Berger C, Bachmann E, Kittler ELW, Odermatt BF and Quesenberry PJ (1996) Expression of the LMP1 oncoprotein in the EBV-negative Hodgkin's disease cell line L-428 is associated with Reed Sternberg cell morphology. Oncogene 13: 947-953
25. Lauritzen AF, Hörding U and Nielsen HW (1994) Epstein Barr virus and Hodgkin's disease: a comparative immunological, in situ hybridization, and polymerase chain reaction study. APMIS 102: 495-500
26. Levine PH, Pallesen G, Ebbesen P, Harris N, Evans AS and Mueller N (1994) Evaluation of Epstein-Barr virus antibody patterns and detection of viral markers in the biopsies of patients with Hodgkin's disease. Int J Cancer 59: 48-50
27. MacLennan KA, Bennett MH, Tu A, Vaughan Hudson B, Easterling J, Vaughan Hudson G and Jelliffe AM (1989) Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer 64: 1686-1693
28. Makgoba MW, Sanders ME, Ginther Luce GE, Dustin ML, Springer TA, Clark EA, Mannoni P and Shaw S (1988a) ICAM-1 a ligand for LFA 1-dependent adhesion of B, T and mycloid cells. Nature 331: 86-88
29. Makgoba MW, Sanders ME, Ginther Luce GE, Gugel EA, Dustin ML, Springer TA and Shaw S (1988b) Functional evidence that intercellular adhesion molecule-1 (ICAM-1) is a ligand for LFA-1-dependent adhesion in T cell-mediated cytotoxicity. Eur J Immunol 18: 637-640
30. Marlin SD and Springer TA (1987) Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell 51: 813-819
31. Mehta CR, Patel NR and Tsiatis AA (1984) Exact significance testing to establish treatment equivalence for ordered categorial data. Biometrics 40: 819-825
32. Merk K, Lennette E, Holm G, Johansson B, Klein G and Björkholm M (1992) Antibodies to Epstein-Barr virus in relation to clinical characteristics of untreated patients with Hodgkin's disease (paper 5). In: An Epidemiological Approach to the Etiology of Hodgkin's Disease. Thesis. Karl Merk, Department of Oncology, Karolinska Institute, Stockholm
33. Morente MM, Piris MA, Abraira V, Acevedo A, Aguilera B, Bellas C, Fraga M, Garcia Del-Moral R, Gomez-Marcos F, Menarguez J, Oliva H, Sanchez-Beato M and Montalban C (1997) Adverse clinical outcome in Hodgkin's disease is associated with loss of retinoblastoma protein expression, high Ki-67 proliferation index, and absence of Epstein Barr virus-latent membrane protein 1 expression. Blood 90: 2429-2436
34. Mueller N, Evans A, Harris NL, Comstock GW, Jellum E, Magnus K, Orentreich N, Polk F and Vogelman J (1989) Hodgkin's disease and Epstein-Barr virus altered antibody pattern before diagnosis. N Engl J Med 320: 689-695
35. Murray RJ, Wang D, Young LS, Wang F, Rowe M, Kieff E and Rickinson AB (1988) Epstein-Barr virus-specific cytotoxic T-cell recognition of transfectants expressing the virus-coded latent membrane protein LMP. J Virol 62: 3747-3755
36. Nadali G, Vinante F, Ambrosetti A, Todeschini G, Veneri D, Zanotti R, Meneghini V, Ricetti MM, Benedetti F, Vassanelli A, Perona G, Chilosi M, Menestrina F, Fiacchini M, Stein H and Pizzolo G (1994) Serum levels of soluble CD30 are elevated in the majority of untreated patients with Hodgkin's disease and correlate with clinical features and prognosis. J Clin Oncol 12: 793-797
37. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R and Masucci MG (1994) The Epstein-Barr virus latent membrane protein-1 (LMP-1) induces interleukin 10 production in Burkitt lymphoma lines. Int J Cancer 57: 240-244
38. Pallesen G, Hamilton-Dutoit JS, Rowe M and Young LS (1991) Expression of Epstein Barr virus (EBV) latent gene products in tumour cells of Hodgkin's disease. Lancet 337: 320-322
39. Pinkus GS, Lones M, Shintaku P and Sad JW (1994) Immunohistochemical detection of Epstein-Barr virus-encoded latent membrane protein in Reed Sternberg cells and variants of Hodgkin's disease. Modern Pathol 7: 454-461
40. Pizzolo G, Vinante F, Nadali G, Ricetti MM, Morosato L, Marrocchella R, Vincenzi C, Semenzato G and Chilosi M (1993) ICAM-1 tissue overexpression associated with increased serum levels of its soluble form in Hodgkin's disease. Br J Haematol 84: 161-162
41. Reedman BM and Klein G (1973) Cellular localization of an Epstein-Barr virus (EBV)-associated complement-fixing antigen in producer and non-producer lymphoblastoid cell lines. Int J Cancer 11: 499-520
42. Sandvej KB, Hamilton-Dutoit SJ and Pallesen G (1993) Influence of Epstein-Barr virus encoded latent membrane protein 1 on the expression of CD23 antigen. CD54 and LFA-3 in Hodgkin and Reed-Sternberg cells. A morphometric analysis. Leukemia Lymphoma 9: 95-101
43. Tullgren O, Grimfors G, Holm G, Johansson B, Svedmyr E, Wedelin C, Mellstedt H, Merk K and Björkholm M (1991) Lymphocyte abnormalities predicting a poor prognosis in Hodgkin's disease. Cancer 68: 768-775
44. Vestlev PM, Pallesen G, Sandvej K, Hamilton-Dutoit SJ and Bendtzen SM (1992) Prognosis of Hodgkin's disease is not influenced by Epstein-Barr virus latent protein. Inr J Cancer 50: 670-671
45. Wang D, Liebowitz D and Kieff E (1985) An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell 43: 831-840
46. Wang D, Liebowitz D, Wang F, Gregory C, Rickinson A, Larson R, Springer T and Kieff E (1988) Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol 62: 4173-4184
47. Wedelin C, Björkholm M, Holm G, Ogenstad S, Johansson B and Mellstedt H (1982) Lymphocyte function in untreated Hodgkin's disease: an important predictor of prognosis. Br J Cancer 45: 70-79
48. Wu TC, Mann RB, Epstein JI, MacMahon E, Lee WA, Charache P, Hayward SD, Kurman RJ, Hayward GS and Ambinder RF (1991) Abundant expression of EBER1 small nuclear RNA in nasopharyngeal carcinoma. Am J Pathol 138: 1461-1469
49. Younes A, Consoli U, Snell V, Clodi K, Kliche KO, Palmer JL, Gruss HJ, Armitage R, Thomas EK, Cabanillas F and Andreeff M (1997) CD30 ligand in lymphoma patients with CD30+ tumours. J Clin Oncol 15: 3355-3362